The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Adcetris is also indicated as monotherapy or in combination with chemotherapy for the treatment of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T-cell ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

T-cell or NK-cell clones. Subclones of these cells may acquire independent genetic changes to produce non-Hodgkin lymphomas and Hodgkin lymphoma. Another speculation is that the multiclonal ...

The Netherlands This consensus report of the EGILS (European Gastro-Intestinal Lymphoma Study) group includes recommendations on the management of gastric extranodal marginal zone B-cell lymphoma of ...

A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...

When a tumor develops, it creates a structure around itself called the tumor stroma, within which blood and lymphatic vessels ...